Explore

Rapid Read Rapid Read
Junction and GRAIL Collaborate to Enhance Access to Galleri Multi-Cancer Early Detection Test

Junction and GRAIL Collaborate to Enhance Access to Galleri Multi-Cancer Early Detection Test

Junction, a platform for diagnostic testing and health data workflows, has announced a collaboration with GRAIL to facilitate scalable access to the Galleri multi-cancer early detection test. This partnership allows healthcare organizations to integrate the Galleri test into their workflows through Junction's diagnostic infrastructure, providing a unified ordering experience and operational support. The Galleri test is a blood test designed to detect signals from over 50 types of cancer, many of which currently lack recommended screening options. The collaboration aims to meet the growing demand for proactive and preventative care by simplifying the operational steps required to offer the Galleri test, making it easier for healthcare providers to integrate it into care delivery.
Trendline Trendline
Sibel Health's ANNE Maternal Platform Receives FDA Clearance for Wireless Monitoring

Sibel Health's ANNE Maternal Platform Receives FDA Clearance for Wireless Monitoring

Sibel Health's ANNE Maternal Platform Receives FDA Clearance for Wireless Monitoring
Rapid Read Rapid Read
FDA Approves At-Home HPV Self-Collection Kit to Enhance Cervical Cancer Screening

FDA Approves At-Home HPV Self-Collection Kit to Enhance Cervical Cancer Screening

The FDA has approved the Onclarity HPV Self-Collection Kit for at-home use, marking a significant advancement in cervical cancer screening. This decision follows a collaboration with the National Cancer Institute to address barriers in preventative care. The kit allows individuals to collect samples at home, which are then tested using the BD Onclarity HPV Assay. This assay identifies high-risk HPV genotypes, which are major contributors to cervical cancer. The approval aims to increase screening accessibility, especially for those who are unscreened or under-screened, which accounts for about 60% of new cervical cancer diagnoses. The initiative is part of a broader effort to improve early detection and health equity.
Rapid Read Rapid Read
EBSCO Report Reveals Clinician Trust in AI Tools Despite Consumer Skepticism

EBSCO Report Reveals Clinician Trust in AI Tools Despite Consumer Skepticism

A report from EBSCO Clinical Decisions highlights a disconnect between clinicians and consumers regarding AI in healthcare. While 89% of clinicians believe AI for clinical decision support (AI-CDS) will improve patient outcomes, 64% of consumers prefer healthcare professionals who do not use AI. The report emphasizes the difference between general AI tools and evidence-based AI-CDS, with the latter gaining more trust from clinicians and consumers. The findings suggest that AI-CDS can reduce cognitive load and improve efficiency, but consumer skepticism remains a challenge.
Rapid Read Rapid Read
FDA Clears At-Home Cervical Cancer Screening Tool to Enhance Early Detection

FDA Clears At-Home Cervical Cancer Screening Tool to Enhance Early Detection

The U.S. Food and Drug Administration (FDA) has approved the Onclarity HPV Self-Collection Kit and the BD Onclarity HPV Assay for at-home use, marking a significant advancement in cervical cancer screening. This tool allows individuals to collect samples at home, which are then analyzed using the BD COR System. The assay is noted for its comprehensive detection of high-risk HPV genotypes, which are responsible for nearly all cervical cancer cases. This development aims to address the gap in screening, as approximately 60% of cervical cancer cases occur in unscreened or under-screened individuals. Waters Corporation, in collaboration with the National Institutes of Health, has been instrumental in this initiative, which is expected to improve early detection and reduce cervical cancer mortality.
Rapid Read Rapid Read
bioAffinity Technologies' CyPath® Lung Test to be Highlighted at Cleveland Clinic Symposium for Early Lung Cancer Detection

bioAffinity Technologies' CyPath® Lung Test to be Highlighted at Cleveland Clinic Symposium for Early Lung Cancer Detection

bioAffinity Technologies, Inc. is set to feature its CyPath® Lung test at the Cleveland Clinic's 'Advances in Early Lung Cancer Detection' symposium on April 16, 2026. The event, which is invitation-only, will focus on the latest developments in lung cancer risk assessment and early detection technologies. Dr. Gordon Downie, the Chief Medical Officer of bioAffinity Technologies, will participate in a panel discussion on lung nodule management. The CyPath® Lung test is a noninvasive diagnostic tool that uses flow cytometry and artificial intelligence to detect cancerous cells in sputum samples. It has demonstrated high sensitivity and specificity in identifying lung cancer in high-risk patients, particularly those with small indeterminate lung nodules. The symposium aims to bring together global leaders in lung cancer research and treatment to discuss emerging technologies and methods for early cancer detection.
Rapid Read Rapid Read
bioAffinity Technologies' CyPath® Lung Test to Feature at Cleveland Clinic Symposium

bioAffinity Technologies' CyPath® Lung Test to Feature at Cleveland Clinic Symposium

bioAffinity Technologies, Inc. will present its CyPath® Lung test at the Cleveland Clinic's annual 'Advances in Early Lung Cancer Detection' symposium on April 16, 2026. The test, which is noninvasive and uses advanced flow cytometry and artificial intelligence, is designed to aid in the early detection of lung cancer in high-risk patients. The symposium will gather global leaders in lung cancer research to discuss emerging diagnostic technologies and the changing epidemiology of lung cancer. Dr. Gordon Downie, bioAffinity's Chief Medical Officer, will participate in a panel on lung nodule management, highlighting the benefits of CyPath® Lung in clinical decision-making and its potential to reduce unnecessary invasive procedures.
Trendline Trendline
AI in Life Sciences Market Projected to Transform Drug Development and Clinical Trials

AI in Life Sciences Market Projected to Transform Drug Development and Clinical Trials

AI in Life Sciences Market Projected to Transform Drug Development and Clinical Trials
Rapid Read Rapid Read
neuroClues Secures €10M to Advance AI-Powered Parkinson’s Diagnosis in U.S. and Europe

neuroClues Secures €10M to Advance AI-Powered Parkinson’s Diagnosis in U.S. and Europe

neuroClues, a French-Belgian medtech company, has raised €10 million in a Series A funding round to support the development and commercialization of its AI-powered eye-tracking device for early diagnosis of neurological disorders, including Parkinson’s disease. The device uses a portable headset to capture infrared images of eye movements, extracting biomarkers that can indicate neurological conditions years before symptoms appear. Having received CE certification in January 2025, neuroClues is now targeting FDA clearance in the United States by 2026. The funding will be used to expand the company’s commercial team and operations in European and U.S. markets. The device aims to address the diagnostic gap in Parkinson’s disease, where early detection is crucial for effective treatment.
Trendline Trendline
Volta Medical Showcases AI Innovations at Heart Rhythm Society 2026

Volta Medical Showcases AI Innovations at Heart Rhythm Society 2026

Volta Medical Showcases AI Innovations at Heart Rhythm Society 2026
Rapid Read Rapid Read
Utah's AI Prescription Pilot Raises Safety Concerns Amid Regulatory Scrutiny

Utah's AI Prescription Pilot Raises Safety Concerns Amid Regulatory Scrutiny

Utah's Office of Artificial Intelligence Policy has approved Doctronic, a health technology startup, to autonomously renew medical prescriptions using AI. This marks the first instance in the U.S. where AI is allowed to handle prescription renewals without direct physician oversight. The pilot program, which spans three phases, begins with physician review of every renewal and gradually reduces oversight to 5-10% of renewals. Concerns have been raised about the safety of this approach, especially after a security research firm demonstrated vulnerabilities in Doctronic's public-facing AI tool. The American Medical Association and the Utah Academy of Family Physicians have expressed objections, citing potential risks to patient safety. The program's design includes monthly reporting requirements and excludes controlled substances, but questions remain about whether AI systems should be regulated as medical devices by the FDA.
Trendline Trendline
Volta Medical Showcases AI Solutions at Heart Rhythm Society 2026 in Chicago

Volta Medical Showcases AI Solutions at Heart Rhythm Society 2026 in Chicago

Volta Medical Showcases AI Solutions at Heart Rhythm Society 2026 in Chicago